1. Background
2. Objectives
3. Methods
3.1. Study Design
3.2. Specimen Collection
3.3. Bacterial Isolation
3.4. Statistical Analysis
3.5. Ethical Consideration
4. Results
| Organisms | Total | Gender | Age Group (y) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Male | Female | P-Value | OR (95% CI) | < 20 | > 20 | P-Value | OR (95% CI) | ||
| Klebsiella spp. | 94 (35.2) | 56 (38.4) | 38 (31.4) | 0.236 | 0.736 (0.442 - 1.224) | 16 (41.0) | 78 (34.2) | 0.410 | 0.748 (0.373 - 1.497) |
| Acinetobacter spp. | 58 (21.7) | 28 (19.2) | 30 (24.8) | 0.268 | 1.389 (0.775 - 2.489) | 11 (28.2) | 47 (20.6) | 0.288 | 0.661 (0.307 - 1.424) |
| Pseudomonas aeruginosa | 23 (8.6) | 14 (9.6) | 9 (7.4) | 0.533 | 0.758 (0.316-1.816) | 4 (10.3) | 19 (8.3) | 0.692 | 0.795 (0.255-2.477) |
| Escherichia coli | 23 (8.6) | 11 (7.5) | 12 (9.9) | 0.490 | 1.351 (0.574 - 3.181) | 2 (5.1) | 21 (9.2) | 0.546 | 1.877 (0.422 - 8.344) |
| Other gram negatives | 8 (3.0) | 3 (2.1) | 5 (4.1) | 0.474 | 2.055 (0.481 - 8.778) | 0 (0.0) | 8 (3.5) | 0.608 | - |
| Total gram-negative organisms | 206 (77.2) | 112 (76.7) | 94 (77.7) | 0.850 | 1.057 (0.595 - 1.878) | 33 (84.6) | 173 (75.9) | 0.230 | 0.572 (0.228 - 1.437) |
| Enterococcus spp. | 36 (13.5) | 20 (13.7) | 16 (13.2) | 0.910 | 0.960 (0.474 - 1.946) | 5 (12.8) | 31 (13.4) | 0.896 | 1.070 (0.389 - 2.945) |
| Staphylococcus aureus | 22 (8.2) | 14 (9.6) | 8 (6.6) | 0.378 | 0.668 (0.270 - 1.649) | 1 (2.6) | 21 (9.2) | 0.218 | 3.885 (0.503 - 29.520) |
| Other gram positives | 3 (1.1) | 0 (0.0) | 3 (2.5) | 0.092 | - | 0 (0.0) | 3 (1.3) | > 0.99 | - |
| Total gram-positive organisms | 61 (22.8) | 34 (23.3) | 27 (22.3) | 0.850 | 0.946 (0.533 - 1.681) | 6 (15.4) | 55 (24.1) | 0.230 | 1.749 (0.696 - 4.393) |
| Total organisms | 267 (100) | 146 (54.7) | 121 (45.3) | - | - | 39 (14.6) | 228 (85.4) | - | - |
a Values are expressed as No. (%).
| Antibiotic | Total | Gender | Age Group | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n/N a) | Female (n/N) | P-Value | OR (95% CI) | < 20 (n/N a) | > 20 (n/N a) | P-Value | OR (95% CI) | ||
| Ceftazidime | 47/200 (23.5) | 23/108 (21.3) | 24/92 (26.1) | 0.426 | 1.304 (0.678 - 2.511) | 4/33 (12.1) | 43/167 (25.7) | 0.116 | 2.514 (0.836-7.564) |
| Cefotaxime or ceftriaxone | 12/40 (30.0) | 4/20 (20.0) | 8/20 (40.0) | 0.301 | 2.667 (0.648 - 10.972) | 0/4 (0.0) | 12/36 (33.3) | 0.297 | - |
| Cefepime | 39/198 (19.7) | 22/107 (20.6) | 17/91 (18.7) | 0.740 | 0.888 (0.438 - 1.797) | 4/32 (12.5) | 35/166 (21.1) | 0.337 | 1.870 (0.615 - 5.687) |
| Meropenem | 78/195 (40.0) | 43/103 (41.7) | 35/92 (38.0) | 0.598 | 0.857 (0.482 - 1.522) | 15/28 (53.6) | 63/167 (37.7) | 0.113 | 0.525 (0.235 - 1.175) |
| Amikacin | 99/199 (49.7) | 60/106 (55.7) | 40/93 (43.0) | 0.056 | 0.579 (0.330 - 1.015) | 9/30 (30.0) | 90/169 (53.3) | 0.019 | 2.658 (1.151 - 6.141) |
| Ciprofloxacin | 48/151 (31.8) | 28/86 (32.6) | 20/65 (30.8) | 0.815 | 0.921 (0.460 - 1.842) | 3/7 (42.9) | 45/144 (31.2) | 0.680 | 0.606 (0.130 - 2.821) |
| levofloxacin | 13/53 (24.5) | 7/24 (29.2) | 6/29 (20.7) | 0.475 | 0.634 (0.180 - 2.229) | 0/4 (0.0) | 13/49 (26.5) | 0.561 | - |
| Trimethoprime-sulfamethoxazole | 32/102 (31.4) | 15/55 (27.3) | 17/47 (36.2) | 0.334 | 1.511 (0.652 - 3.501) | 4/15 (26.7) | 28/87 (32.2) | 0.771 | 1.305 (0.382 - 4.463) |
| Colistin | 67/67 (100) | 33/33 (100) | 34/34 (100) | - | - | 10/10 (100) | 57/57 (100) | - | - |
a n/N (%); the number of sensitive isolates/total number of examined isolates (percent).
| Antibiotic | Total | Gender | Age Group | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n/N a) | Female (n/N) | P-Value | OR (95% CI) | < 20 (n/N a) | >20 (n/N a) | P-Value | OR (95% CI) | ||
| Vancomycin | 26/74 (35.1) | 15/40 (37.5) | 11/34 (32.3) | 0.644 | 0.797 (0.305 - 2.087) | 1/9 (11.1) | 25/65 (38.5) | 0.147 | 5.000 (0.589 - 42.415) |
| Clindamycin | 10/39 (25.6) | 6/21 (28.6) | 4/18 (22.2) | 0.726 | 0.714 (0.166 - 3.075) | 1/4 (25.0) | 9/35 (25.7) | 1.000 | 1.038 (0.095 - 11.296) |
| Gentamicin | 14/20 (70) | 8/13 (61.5) | 6/7 (85.7) | 0.354 | 3.750 (0.342 - 41.081) | 0/0 (0.0) | 14/20 (70.0) | - | - |
| Ciprofloxacin | 10/44 (22.7) | 6/26 (23.1) | 4/18 (22.2) | 1.000 | 0.952 (0.226 - 4.011) | 1/2 (50.0) | 9/42 (21.4) | 0.407 | 0.273 (0.015 - 4.801) |
| Ampicillin | 9/37 (24.3) | 5/20 (25.0) | 4/17 (23.5) | 1.000 | 0.923 (0.204 - 4.179) | 1/5 (20.0) | 8/32 (25.0) | 1.000 | 1.333 (0.129 - 13.743) |
| Linezolid | 31/31 (100) | 16/16 (100) | 15/15 (100) | - | - | 5/5 (100) | 26/26 (100) | - | - |
a n/N (%); the number of sensitive isolates/total number of examined isolates (percent).